Search
Research
Receptor mutation is not a common mechanism of naturally occurring glucocorticoid resistance in leukaemia cell linesGlucocorticoids (GCs) are among the most important drugs for the treatment of acute lymphoblastic leukaemia (ALL).
Research
Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumorsEffective antitumor CD8 T cell responses may be activated by directly targeting the innate immune system within tumors.
A first of its kind research program at The Kids Research Institute Australia aims to develop new strategies to better treat Aboriginal and Torres Strait Islander children with cancer.
News & Events
The Kids cancer researcher named a Superstar of STEMThe Kids Research Institute Australia brain cancer researcher, Dr Jessica Buck will today join the ranks of a select group of brilliant female scientists.
News & Events
How to win friends and influence people: Cancer researchers talk the talk for big resultsIn the field of cancer research, lobbying efforts by the The Kids Cancer Centre have contributed to major initiatives including Australia’s first personalised medicine program for children with high-risk cancer, and a mission to boost survival rates in brain cancer patients.
News & Events
Funding boost to melanoma researchA The Kids Research Institute Australia researcher will investigate new ways to harness the body’s own immune system to fight melanoma, thanks to Cancer Council WA funding.
News & Events
Adventurers deliver on a promise to help kids with cancerA state of the art 3D molecular imager that will help researchers monitor how brain tumours grow has been delivered to the Telethon Institute.
People
Professor Nick GottardoHead of Paediatric and Adolescent Oncology and Haematology, Perth Children’s Hospital; Co-head, Brain Tumour Research Program, The Kids Research Institute Australia
News & Events
Pioneering new treatments for leukaemia in children with Down syndromeA team of world-leading scientists has secured $5 million in funding from the Leukaemia and Lymphoma Society to advance the fight against leukaemia in children with Down syndrome.
Research
Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in gliomaWe discovered a previously unknown major resistance mechanism in glioma in that most EGFR domain III-targeting antibodies do not neutralize EGFRvIII